SS-31 vs MOTS-c: prices, identity and regulatory status (2026)
SS-31 and MOTS-c are different research compounds, not substitutes for each other: SS-31 is a 4-amino-acid peptide (C32H49N9O5); MOTS-c is a 16-amino-acid peptide (C101H152N28O22S2). Neither product has a current in-stock price right now. SS-31 shares its active ingredient with an FDA-approved prescription medicine; MOTS-c has no Drugs@FDA application.
SS-31 vs MOTS-c: current prices and packages
| Compared property | SS-31 | MOTS-c |
|---|---|---|
| Category | Longevity | Longevity |
| Compared package | 10mg | 10mg |
| Lowest current price | No current in-stock price | No current in-stock price |
| Price per labelled mg | — | — |
| Package sizes | 10mg, 30mg, 50mg | 5mg, 10mg, 20mg, 40mg |
| Vendors with current prices | 0 | 0 |
| Form at this package | No listing | No listing |
| Stock | Out of stock | Out of stock |
Prices exclude shipping. The price per labelled mg is always given per mg, so different package sizes compare directly; it is shown only for single-compound vials and powders with a labelled mass. Blends, capsules, liquids and IU-labelled packages are compared by package total.
Identity, regulatory status and registered research
| Compared property | SS-31 | MOTS-c |
|---|---|---|
| Molecular formula | C32H49N9O5 | C101H152N28O22S2 |
| Molecular weight | 639.8 g/mol | 2174.6 g/mol |
| Sequence | H-D-Arg-Tyr(2,6-diMe)-Lys-Phe-NH2 (4 residues) | H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH (16 residues) |
| CAS Registry Number | 736992-21-5 | 1627580-64-6 |
| Registered clinical trials | 30 (3 active) · Phase 4: 1, Phase 3: 4, Phase 2: 15 | 1 (1 active) · Phase 2: 1 |
| Human intervention studies | 5 | None recorded |
| US regulatory status | FDA-approved prescription medicine with this active ingredient: Forzinity (NDA 215244; checked October 7, 2026)MarketedFORZINITY · NDA 215244 · 2025Research listings are not these medicines. | No Drugs@FDA application (checked October 7, 2026) · Drugs@FDA search |
Identity data: PubChem, FDA GSRS and EPA records; registry counts: ClinicalTrials.gov; status: Drugs@FDA. A matching name does not verify the contents of a supplier's lot.
Key human studies
SS-31
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024
- Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet journal of rare diseases, 2024
- Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology, 2023
MOTS-c
No human intervention study is recorded in the research library for this identity.
MOTS-c research profile →Studies are listed as records, newest first; they are not evidence that a research product is safe or effective.
Where to buy each compound
SS-31
SS-31 is a catalogue entry whose compound-specific reference review has not yet been completed.
No vendor has a current in-stock price for this package.
SS-31 prices →Price history →MOTS-c
MOTS-c is a catalogue entry whose compound-specific reference review has not yet been completed.
No vendor has a current in-stock price for this package.
MOTS-c prices →Price history →Related comparisons
Questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price, except that the labelled featured partner, LA Peptides, is pinned first; “Cheapest” always marks the lowest price. PeptideTech earns a commission when you buy through a link.
Full method →